Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
暂无分享,去创建一个
A. Konstas | W. C. Stewart | E. Sharpe | K. T. Holmes | A. Kolker | J. Rieser | D. Day | H. Chopra | W. Lee
[1] A. Polis,et al. The Efficacy and Safety of Dorzolamide as Adjunctive Therapy to Timolol Maleate Gellan Solution in Patients with Elevated Intraocular Pressure , 1998 .
[2] P. Watson. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. , 1998, Ophthalmology.
[3] J. Stjernschantz,et al. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. , 1996, Ophthalmology.
[4] A. Alm,et al. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. , 1995, Ophthalmology.
[5] P. Kaufman,et al. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey , 1989 .
[6] S. Nilsson,et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. , 1989, Experimental eye research.
[7] E. Bárány. A pharmacologist looks at medical treatment in glaucoma--in retrospect and in prospect. , 1979, Ophthalmology.
[8] A. Bill,et al. Uveoscleral drainage of aqueous humour in human eyes. , 1971, Experimental eye research.